REPRODUCTIVE ENDOCRINOLOGY
|
|
- Darrell Harrell
- 6 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY VOL. 79, NO. 1, JANUARY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. REPRODUCTIVE ENDOCRINOLOGY Treatment of hyperandrogenic alopecia in women Enrico Carmina, M.D., a and Rogerio A. Lobo, M.D. b University of Palermo, Palermo, Italy Objective: To determine the effectiveness of various antiandrogens for the treatment of premenopausal women with hyperandrogenic alopecia. Design: Randomized, unmasked trial of three treatments in 36 hyperandrogenic women with alopecia and observation, without treatment, in 12 other similar patients. Setting: Endocrinologic outpatient practice in Italy. Participant(s): A total of 48 hyperandrogenic women with alopecia and 30 age- and weight-matched controls for the assessment of androgen levels. Intervention(s): Randomization to cyproterone acetate (50 mg) with ethinyl estradiol (EE) in a reverse sequential regimen; flutamide (250 mg) or finasteride (5 mg) daily; all for 1 year. Twelve similar patients were observed without treatment for 1 year. Main Outcome Measure(s): Ludwig scores for hair thinning as well as patient and investigator assessments of treatment effectiveness. Result(s): Flutamide resulted in a reduction of 21% in Ludwig scores ( to ). The other treatment effects were not statistically significant. Patient and investigator assessments showed a similar trend. Conclusion(s): Flutamide at a dose of 250 mg daily induced a modest improvement in alopecia after 1 year, whereas cyproterone acetate and finasteride were not effective. Treatment for more than 1 year may be required for better results. (Fertil Steril 2003;79: by American Society for Reproductive Medicine.) Key Words: Alopecia, hyperandrogenism, antiandrogens Received December 19, 2001; revised and accepted July 5, Reprint requests: Rogerio A. Lobo, M.D., Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, 630 West 168 Street, New York, New York (FAX: ; E- mail: ral35@columbia.edu). a Department of Obstetrics and Gynecology. b Department of Obstetrics and Gynecology, Columbia University, College of Physicians and Surgeons, New York, New York /03/$30.00 PII S (02)04551-X Androgenic alopecia is a common form of alopecia in which androgens gradually transform normal-sized scalp hair follicles to miniaturized hair follicles. Progressively, there is a thinning of scalp hair and a pattern of hair loss that is greatest in the frontal/parietal regions (1, 2). Although it is generally believed that the pathogenesis of hyperandrogenic alopecia is related to an excessive activity of androgen on the scalp, in many affected women circulating androgen levels are normal (3, 4) and an increased scalp sensitivity to androgens has been suggested (2). Among those women with increased circulating levels of androgen, no particular pattern of increased androgen production has been linked with hyperandrogenic alopecia (3, 5), although some investigators have suggested the presence of adrenal hyperandrogenism (4). In the setting where circulating androgens are normal, it is likely that scalp sensitivity to androgens is the important component of the pathophysiology. Studies of peripheral androgen metabolism in alopecia have been inconclusive. Although it has been shown that type I 5 -reductase activity is increased in female hyperandrogenic alopecia, this may be the consequence of increased circulating androgens (6). On the other hand, we and other researchers have shown that women with hyperandrogenic alopecia have a characteristic pattern of increased 5 -reduced androgen metabolites, particularly 3 -androstanediol sulfate (5, 7). These androgen metabolites, however, are highly dependent on circulating androgens as substrate, and the sulfate derivatives correlate well with adrenal androgens (8). Treatment of androgenic alopecia has been disappointing (2, 9). In contrast to the reasonably good results obtained in women with hirsutism or acne, classic antiandrogen therapies have been generally unsuccessful. In the past several years antiandrogenic agents have become available and have been studied for the 91
2 treatment of hirsutism (10). In this study, we assessed the effects of two agents (flutamide and finasteride) in women with hyperandrogenic alopecia (11, 12). We compared the effects of these treatments to the effects of a well-studied antiandrogen cyproterone acetate (13). In this study we also had the opportunity to assess the effects of no treatment. TABLE 1 Baseline mean Ludwig scores and serum androgens in groups of women with hyperandrogenic alopecia who were randomized to treatment or were observed for 1 year. MATERIALS AND METHODS Alopecia scores T (ng/dl) Unbound T (pg/ml) DHEAS ( g/ml) Forty-eight hyperandrogenic women were studied (mean age 25 2 years, mean body mass index [BMI] ) who presented consecutively with the chief complaint and diagnosis of androgenic alopecia over a period of 3 years. Only premenopausal women with increased serum androgens were included. Serum androgens that were higher than the mean 2 SD of levels in ovulatory controls were considered elevated. Frontal hair thinning was assessed as grade I, II, or III according to the Ludwig classification (14). A picture of the frontal parietal region was obtained in each patient and was used for comparisons at the end of the treatment. Mild hirsutism (evaluated by Ferriman-Gallwey- Lorenzo index) was present in 10 patients (21%) and menstrual irregularities (oligomenorrhea) were present in 20 women (42%) with androgenetic alopecia. Thirty normal ovulatory women, matched for age and body weight, served as controls. In all patients and controls, a blood sample was obtained during the follicular phase of the cycle (days 5 6), after an overnight fast for T, unbound T, and DHEAS. These values were used to confirm the presence of hyperandrogenism in all 48 subjects with androgenic alopecia. Thirty-six women were randomized to one of three treatments, each composed of 12 subjects: 1. cyproterone acetate (CPA) (50 mg/day 25 g of ethinyl estradiol [EE]) in a reverse sequential regimen (CPA from day 5 to day 15 of the cycle EE from day 5 to day 25 of the cycle) (15); 2. flutamide (250 mg/day); and 3. finasteride (5 mg/day). A dose of 250 mg was chosen for flutamide to minimize the potential for hepatic toxicity (16). Twelve women who were recruited for the study refused any treatment and were observed for 1 year without any therapy. These women had similar characteristics and the same degree of alopecia as women in the treatment groups. At the end of treatment (or observation) the following evaluation procedures were carried out: 1. Ludwig grade of frontal hair thinning. 2. Patient self-assessment (using a questionnaire [17], consisting of four questions: appearance of the hair, growth of hair, slowing down of hair loss, and general satisfaction with the therapy). 3. Investigator assessment. The hair density in the frontal parietal region was compared to that observed before treatment using a 7-point rating scale: greatly decreased ( 3), moderately decreased ( 2), slightly decreased ( 1), no CPA (n 12) Flutamide (n 12) Finasteride (n 12) Observation (n 12) No significant differences between groups were found. change (0), slightly increased ( 1), moderately increased ( 2), and greatly increased ( 3). All assessments were carried out by one of the authors (EC). Possible side effects and liver function tests were assessed at 3-month intervals. Institutional review board approval was obtained and all patients gave written informed consent. All subjects in this study were not dieting or receiving any medication for at least 3 months before starting the study. Serum hormone levels were measured by RIAs, which have been previously validated in our laboratory. Intra- and interassay coefficients of variation were less than 6% and 12%, respectively (18, 19). Statistical Analysis Mann-Whitney U was the test used to compare patients and controls; the response to therapy was assessed by analysis of variance. P.05 was considered statistically significant. Results are expressed as mean SE. RESULTS Women with alopecia in this study had significantly (P.01) increased levels of T, unbound T, and DHEAS in comparison with normal controls. Mean scores for alopecia and serum androgens were similar in each of the treatment groups (Table 1). After 1 year of treatment, only flutamide induced a significant, although small, decrease in Ludwig scores (from to , P.05). The changes with the other agents were smaller and not significant. Flutamide resulted in a 21% decrease in scores (Fig. 1). The self-assessment evaluation also showed that flutamide gave the best results. Eight flutamide-treated patients reported the slowing down of hair loss and 5 of them declared general satisfaction with this treatment. However, improvement of general hair appearance and regrowth of hair were observed in only 3 patients (Table 2). With the 92 Carmina and Lobo Treatment of alopecia Vol. 79, No. 1, January 2003
3 FIGURE 1 Percent decrease of Ludwig scores in four groups of women with hyperandrogenic alopecia. Open bar, cyproterone acetate (CPA); solid bar, flutamide; striped bar, finasteride; dotted bar, observation group. Only flutamide ( 21%) showed a significant decrease as indicated by asterisk (P.05). FIGURE 2 Investigator assessment of scalp hair changes in four groups of women with hyperandrogenic alopecia. Open bar, cyproterone acetate (CPA); solid bar, flutamide; striped bar, finasteride; dotted bar, observation group. The improvement in assessment scores for flutamide was significantly (P.05) better than that for finasteride and the observation group as indicated by the asterisks. other agents, less favorable results were reported (Table 2). In patients treated with CPA, 3 observed slowing down of hair loss and general satisfaction with this treatment. Only one patient on finasteride and one in the observational group reported a slowing down of hair loss and were pleased with these results. The scores of investigator assessment also indicated that the best results were obtained with flutamide with a mean score of (Fig. 2). However, this was not significant when compared to CPA (mean ), but was greater compared to finasteride and the observation group (for both mean ; P.05). In two patients, after 6 months of treatment with flutamide, a mild elevation of liver enzymes was observed (transaminases were very mildly elevated; 20% above the TABLE 2 The number of patients who reported improvement of alopecia using self-assessment with a standardized questionnaire (16). General hair appearance Hair regrowth Slowdown of hair loss General satisfaction with the therapy CPA (n 12) Flutamide (n 12) Finasteride (n 12) Observation (n 12) normal range). This was not thought to preclude treatment, which was continued with the full approval and knowledge of the patients. Liver function in these 2 patients was carefully evaluated every month. No further increase of liver enzymes was observed and 2 months after the end of the treatment the liver enzyme levels returned to normal. No other side effects were observed with flutamide. No side effects were reported during treatment with CPA or finasteride. DISCUSSION Although increased serum androgens have a major role in the pathogenesis of female hyperandrogenic alopecia, treatment has been found to be generally unsuccessful (2, 9). Several studies have compared the effects of different antiandrogens in the treatment of hirsutism (10), yet no such data exist for the treatment of hyperandrogenic alopecia (1). In this study we assessed and compared the effects of three different agents in the treatment of women with hyperandrogenic alopecia. Cyproterone acetate is a classic antiandrogen that is used widely in Europe and in Canada, but has not been marketed in the United States. We chose the classic regimen of a high dose (50 mg/day) in a reverse sequential regimen in combination with EE (15), although several other doses of CPA may be used. Previously, we had shown that high doses give better results than low doses in women with hirsutism (20). The second agent in this trial, flutamide, is a powerful competitive inhibitor of the androgen receptor and has been FERTILITY & STERILITY 93
4 shown to be effective in decreasing hirsutism (10, 11). It has been given in doses of mg/day; lower doses ( mg/day) have also been used (11, 16). Because flutamide has been associated with severe liver damage (21, 22), we chose to use 250 mg/day (16). The third agent, finasteride, is an inhibitor of 5 -reductase type II (23). It has been known for several years that 5 -reductase activity is increased in the androgenetic alopecia scalp, and this probably contributes to the pathogenesis of hair loss (24, 25). Finasteride, at a dose of 1 mg/day, has reduced male hair loss and has been approved for the treatment of male balding (23). Recently, a large trial (26) in women showed that finasteride (1 mg/day) was ineffective in female androgenetic alopecia. In this particular study, only postmenopausal women were evaluated. We considered that it is possible that the pathogenesis of postmenopausal androgenic alopecia and premenopausal hyperandrogenic alopecia are different. We decided to include finasteride in our trial and to use a larger dose, 5 mg/day, which has been shown to be beneficial for the treatment of hirsutism (12). Our study showed that all the agents had a small effect on the treatment of hyperandrogenic alopecia. However, there were some important differences. Although finasteride, at a dose of 5 mg/day, was ineffective and its effects were similar to that of the observation group, both flutamide and CPA exhibited some improvement of the alopecia. The best results were obtained with flutamide, which resulted in a 21% improvement of Ludwig scores, a reduction of hair loss (as reported by a self-assessment questionnaire in 8 of 12 patients, and a slight mean improvement of alopecia ( 1) by investigator assessment. These differences were statistically significant in comparison with the observation group who had no treatment. Although the total objective improvement was small and only a few patients (3 of 12) reported a subjective regrowth of hair, this may be due to the characteristics of cycles of hair growth on the scalp. The anagen phase of scalp hair growth has a duration of several years (from 2 to 8 years) and is much longer than that on the face (about 3 months). Therefore, it is possible that a protocol involving a very much longer observation period is needed to obtain significant findings of regrowth of scalp hair (27). It is unclear why, as opposed to treatment in men, finasteride is not effective in female androgenic alopecia. However, we propose that the scalp concentration of 5 -reductase isoenzymes in men and hyperandrogenic women may explain these differences. Finasteride is an inhibitor of type II 5 -reductase and in hyperandrogenic women with hirsutism or acne, there is mostly an increase of type I 5 reductase. It is conceivable, therefore, that in hyperandrogenic women with alopecia, scalp type I 5 -reductase predominates as it does in other hyperandrogenic women. Some evidence for this has been provided (28). Our study was limited by the fact that there were only 12 women in each group. Only a multicenter trial may be able to recruit more patients, and this may have resulted in more significant findings. We also did not treat women with placebo but have included an observational group whose characteristics of androgens and objective hair findings were similar. Although we have suggested that a longer treatment protocol may be necessary, a concern exists with the use of flutamide. Two of 12 women demonstrated mild elevations in liver enzymes, which were reversible, at the low dose of 250 mg used in this study. However, prolonged treatment may further increase this risk and although we are not proposing that only flutamide be used for alopecia, we present our findings using objective criteria. Perhaps newer agents in this class with less propensity for hepatocellular toxicity would be beneficial for prolonged treatment of hyperandrogenic alopecia. We also did not compare the use of spironolactone in this setting. Because it is difficult to recruit a large number of women with androgenic alopecia, we compared only flutamide, finasteride, and CPA. In conclusion, we have shown that a pure antiandrogenblocking agent, flutamide, improves hyperandrogenic female alopecia to a modest degree. Although this effect is relatively small and is mostly characterized by a reduction in hair loss, it is possible that longer treatment may result in better and more substantial regrowth of scalp hair. Our data also would suggest that finasteride is ineffective in this setting. References 1. Olsen EA. Androgenetic alopecia. In: Olsen EA, editor. Disorders of hair growth: diagnosis and treatment. New York: McGraw-Hill, 1994: Carmina E, Lobo RA. Hirsutism, alopecia and acne. In: Becker KL, editor. Principles and practice of endocrinology and metabolism, 3rd ed. Philadelphia: Lippincott, 2001: Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive women presenting with alopecia. J Am Acad Dermatol 1988;19: Vexiau P, Chaspoux C, Boudou P, Fiet J, Abramovici Y, Rueda MJ, et al. Role of androgens in female-pattern androgenetic alopecia, either alone or associated with other symptoms of hyperandrogenism. Arch Dermatol Res 2000;292: Legro RS, Carmina E, Stanczyk FZ, Gentzschein E, Lobo RA. Alterations in androgen conjugate levels in women and men with alopecia. Fertil Steril 1994;62: Kutten F, Mauvais-Jarvisi P. Testosterone 5 -reduction in the skin of normal subjects and in patients with abnormal sex development. Acta Endocrinol (Copenh) 1975;79: Montalto J, Whorwood CB, Funder JW, Yong AB, Callan A, Davies HE, et al. Plasma C19 steroid sulphate levels and indices of androgen bioavailability in female pattern androgenic alopecia. Clin Endocrinol (Oxf) 1990;32: Carmina E, Gentzschein E, Stanczyk FZ, Lobo RA. Substrate dependency of C19 conjugates in hirsute hyperandrogenic women and the influence of adrenal androgen. Hum Reprod 1995;10: Meidan VM, Touitou E. Treatment for androgenetic alopecia and alopepcia areata: current options and future prospects. Drugs 2001;61: Carmina E. A risk benefit assessment of pharmacological therapies for hirsutism. Drug Safety 2001;24: Moghetti P, Castello R, Negri C, Tosi F, Magnani CM, Fontanarosa MC, et al. Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil Steril 1995;64: Carmina and Lobo Treatment of alopecia Vol. 79, No. 1, January 2003
5 12. Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995;80: Underhill R, Dewhurst J. Further clinical experience in the treatment of hirsutism with cyproterone acetate. Br J Obstet Gynaecol 1979;86: Ludwig E. Classification of the types of androgenic alopecia (common baldness occurring in the female sex). Br J Dermatol 1977;97: Hammerstein J, Meckies J, Leo-Rossberg I, Moltz L, Zielske F. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem 1975;6: Muderris II, Bayram F, Guven M. A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 2000;73: Barber BL, Kaufman KD, Kozloff RC. A hair growth questionnaire for use in the evaluation of therapeutic effects in men. J Dermatol Treat 1998;9: Lobo RA, Kletzky OA, Kaptein EM, Goebelsmann U. Prolactin modulation of dehydroepiandrosterone sulfate secretion. Am J Obstet Gynecol 1980;138: Stanczyk FZ, Chang L, Carmina E, Putz Z, Lobo RA. Is 11 -hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate? Am J Obstet Gynecol 1991;166: Carmina E, Lobo RA. Gonadotropin releasing hormone agonist therapy for hirsutism is effective as high dose cyproterone acetate but results in a longer remission. Hum Reprod 1997;84: Wysowski DK, Freiman JP, Tourtelot JB, Horton ML. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118: Wysowski DK, Foucroy IL. Flutamide hepatotoxicity. J Urol 1996;155: Rittmaster RS. Finasteride. N Engl J Med 1994;330: Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994;79: Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenic alopecia. J Am Acad Dermatol 1999; 41: Price VH, Roberts JL, Hordinsky M, Olsen EO, Savin R, Bergfeld W, et al. Lack of efficacy of finasteride in postmenopausal women with androgenic alopecia. J Am Acad Dermatol 2000;43: Paus R, Costarelis G. The biology of hair follicles. N Engl J Med 1999;341: Sawaya ME, Price VH. Different levels of 5 -reductase type I and II, aromatase and androgen receptor in hair follicles of women and men with androgenic alopecia. J Invest Dermatol 1997;109: FERTILITY & STERILITY 95
FEMALE PATTERN HAIR LOSS
STUDY Finasteride Treatment of Female Pattern Hair Loss Matilde Iorizzo, MD; Colombina Vincenzi, MD; Stylianos Voudouris, MD; ianca Maria Piraccini, MD, PhD; Antonella Tosti, MD Objective: To evaluate
More informationSummary. Introduction. Dow Stough, MD
Original Contribution Blackwell Publishing ORIGINAL Inc CONTRIBUTION Dutasteride improves male pattern hair loss in a randomized study in identical twins Dow Stough, MD The Dermatology Clinic, Hot Springs,
More informationKey words: Androgenetic alopecia, Þ nasteride, topical gel
Brief Report Comparing the therapeutic effects of Þ nasteride gel and tablet in treatment of the androgenetic alopecia Zohreh Hajheydari, Jafar Akbari 1, Majid Saeedi 1, Leila Shokoohi Department of Dermatology,
More informationMale pattern baldness is the most common type of balding among males. It affects roughly, 50% of men by the age of 50,
Dihydrotestosterone (DHT) Male pattern baldness is the most common type of balding among males. It affects roughly, 30% of men by the age of 30, 50% of men by the age of 50, 57% of men by the age of 60.
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationEffect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride
Report Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride Jae Yoon Jung 1, MD, Je Ho Yeon 1, MD, Jee Woong Choi 1, MD, Soon Hyo Kwon 1, MD, Beom Joon Kim 2, MD,
More informationReproductive DHT Analyte Information
Reproductive DHT Analyte Information - 1 - DHT Introduction Dihydrotestosterone (DHT) together with other important steroid hormones such as testosterone, androstenedione (ASD) and dehydroepiandrosterone
More informationLack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 43:
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/12275255 Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
More informationThe physiology of normal androgen production in
Mayo Clin Proc, April 2004, Vol 79 (Supplement) Formulations and Use of Androgens S3 Supplement Article Formulations and Use of Androgens in Women MICHELINE C. CHU, MD, AND ROGERIO A. LOBO, MD The physiology
More information1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride
1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride
More informationFINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM
750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride
More informationCombined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients
Dermatologic Therapy, Vol. 28, 2015, 303 308 Printed in the United States All rights reserved VC 2015 Wiley Periodicals, Inc. DERMATOLOGIC THERAPY ISSN 1396-0296 ORIGINAL PAPERS Combined treatment with
More informationAffirming Care of the Transgender Patient
Mountain West AIDS Education and Training Center Affirming Care of the Transgender Patient Jessica Rongitsch, MD, FACP This presentation is intended for educational use only, and does not in any way constitute
More informationUnderstanding combined oral contraception
Understanding combined oral contraception Paula Briggs, FFSRH Consultant in Community Sexual and Reproductive Health Southport and Ormskirk NHS Hospital Trust May Logan Centre, Bootle, L20 5DQ paulaeb@aol.com
More informationEFFECTS OF REVIVOGEN SCALP THERAPY ON TESTOSTERONE METABOLISM IN RECONSTRUCTED HUMAN EPIDERMIS
IN VITRO BIOLOGICAL TESTING BIOalternatives The state-of-the-art laboratory Proposal n : AD070315C-2 Study n : AD070315B EFFECTS OF REVIVOGEN SCALP THERAPY ON TESTOSTERONE METABOLISM IN RECONSTRUCTED HUMAN
More informationAndrogenes and Antiandrogenes
Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important
More informationPriyam Bhaskar Rai, Pragya Khushwaha*, Nitish Jain, Swati Gupta
International Journal of Research in Dermatology Rai PB et al. Int J Res Dermatol. 2018 Aug;4(3):386-390 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20183163
More informationMALE PATTERN BALDNESS
MALE PATTERN BALDNESS Male-pattern hair loss (MPHL), also known as androgenic alopecia and male pattern baldness, is hair loss that occurs due to an underlying susceptibility of hair follicles to shrinkage
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationAlthough women produce only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Mary Lake Polan, MD, PhD, MPH Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Chair Emeritus,
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationFigure 2. RESULTS DATA ANALYSIS
ANDROGEN PARAMETERS IN HIRSUTE AND NORMAL FEMALE PATIENTS: IS THERE A ROLE FOR THE FREE ANDROGEN INDEX (FAI)? Castracane VD 1, Childress E 1, Tawwater B 1, Vankrieken L 2, El Shami AS 2 ( 1 Department
More informationControl of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy
British Journal of Dermatology (1986) 115, 269-274. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy R.S.SAWERS, VALERIE A.RANDALL* AND
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. FINASTERIDE 1 MG FILM-COATED TABLETS (finasteride)
PACKAGE LEAFLET: INFORMATION FOR THE USER FINASTERIDE 1 MG FILM-COATED TABLETS (finasteride) Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More informationDr Tarza Jamal Pharmacology Lecture 2
Contraceptives and androgen hormone Contraceptives: Currently, interference with ovulation is the most common pharmacologic intervention for preventing pregnancy. Major classes of contraceptives 1. Combination
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThe Science of. NUTRICULA Longevity Journal
32 December, 2011 The Science of 33 NUTRICULA Longevity Journal As men age, there is often a decline in libido and sexual function. This decline frequently interferes in intimacy within romantic relationships,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,
More informationProviron. Proviron Functions & Traits: (Mesterolone)
Proviron (Mesterolone) Proviron represents one of the oldest anabolic androgenic steroids on the market. A product of the giant pharmaceutical company Schering, it would first appear in 1934. Officially
More informationIcd-10 low levels of testosterone
Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases
More informationSkin metabolism of steroid hormones as endogenous compounds?
Skin metabolism of steroid hormones as endogenous compounds? Van Luu-The Department of Molecular Medicine Laval University Québec, Canada This work has been supported by L Oréal Research Steroid hormones
More informationHair loss in women is an increasingly frequent problem. The
Hair Loss in Women Francisco M. Camacho-Martínez Female pattern hair loss (FPHL) is a clinical problem that is becoming more common in women. Female alopecia with androgen increase is called female androgenetic
More informationCONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS
CONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS 13 Septembre 2018 Quebec, Canada 1 ENDOCEUTICS No. 1 Innovative pharmaceutical company in menopausal women s health in the world 2 Facilities Head
More informationInternational Journal of Clinical Pharmacology and Therapeutics, Vol. No. /2014 (1-8)
International Journal of Clinical Pharmacology and Therapeutics, Vol. No. /2014 (1-8) Original 2014 Dustri-Verlag Dr. K. Feistle ISSN 0946-1965 DOI 10.5414/CP202119 e-pub: July 30, 2014 A novel finasteride
More informationThe ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate
The ICL Insider February 2017 Volume 2, Issue 2 Lab Testing: Testosterone In This Issue Testosterone shashtilak@iclabs.ca Next Issue: Expected Release April 2017 The Debate Aging is accompanied by various
More informationEVIDENCE-BASED DERMATOLOGY: REVIEW. Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia
EVIDENCE-BASED DERMATOLOGY: REVIEW Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia A Systematic Review José Manuel Mella, MD; María Clara Perret, MD; Matías Manzotti, MD; Hugo Norberto
More informationPros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery
Pros and Cons of Hormone Testing in Different Body Fluids with Different Routes of Hormone Delivery David T Zava, PhD ZRT laboratory A Guide to Steroid Hormone Testing in Different Body Fluids Following
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationNatural estrogens estradiol estrone estriol
Estrogens Natural estrogens estradiol estrone estriol Nonsteroidal synthetic Diethylstilbestrol Chlorotrianisene Methallenestril Steroidal synthetic Ethinyl estradiol Mestranol Quinestrol To decrease some
More informationSue Marty, Ph.D., D.A.B.T. The Dow Chemical Company TERA Endocrine Workshop April 23, 2013
Sue Marty, Ph.D., D.A.B.T. The Dow Chemical Company TERA Endocrine Workshop April 23, 2013 Agenda Value of WoE/MoA determinations in EDSP Information used to examine potential endocrine activity and/or
More informationPRODUCT INFORMATION. PROPECIA (finasteride) Tablets NAME OF THE MEDICINE
PRODUCT INFORMATION PROPECIA (finasteride) Tablets NAME OF THE MEDICINE Finasteride is described chemically as: N-(1,1-dimethylethyl)-3-oxo-4-aza-5 -androst-1-ene-17 carboxamide. The CAS No is 98319-26-7.
More informationIssues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationClinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일
Clinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일 Development of 5ARI Discovery of 5AR type I and type II Pharmacodynamic and pharmacokinetic
More informationPRODUCT INFORMATION. PROPECIA (finasteride) Tablets NAME OF THE MEDICINE
WPC-MK0906-PPC-1T-022012 1 PRODUCT INFORMATION PROPECIA (finasteride) Tablets NAME OF THE MEDICINE Finasteride is described chemically as: N-(1,1-dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17βcarboxamide.
More informationMALE HORMONE THERAPY OPTIONS
MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women s logo is placed throughout
More informationPRODUCT INFORMATION. Apo-Finasteride 1 (Finasteride Film-coated Tablets 1 mg)
NAME OF THE MEDICINE PRODUCT INFORMATION Apo-Finasteride 1 (Finasteride Film-coated Tablets 1 mg) Finasteride is described chemically as: N-(1,1-dimethylethyl)-3-oxo-4-aza-5 -androst-1-ene- 17 carboxamide.
More informationTestosterone Topical/Buccal/Nasal
BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationProstate enlargement, also known as benign prostatic hyperplasia
REPORTS Differences in Alpha Blocker Usage Among Enlarged Prostate Patients Receiving Combination Therapy with 5ARIs Michael Naslund, MD, MBA; Libby Black, PharmD; Michael Eaddy, PharmD, PhD; LaKeasha
More informationMaturitas 67 (2010) Contents lists available at ScienceDirect. Maturitas. journal homepage:
Maturitas 67 (2010) 39 45 Contents lists available at ScienceDirect Maturitas journal homepage: www.elsevier.com/locate/maturitas Review Androgen deficiency in women; role of accurate testosterone measurements
More informationANNEX 3 TO THE DRAFT REPORT OF THE OECD VALIDATION OF THE RAT HERSHBERGER BIOASSAY: PHASE 2
ANNEX 3 TO THE DRAFT REPORT OF THE OECD VALIDATION OF THE RAT HERSHBERGER BIOASSAY: PHASE 2 Hershberger Assay Interlaboratory Study: Statistical analysis of phase 2 data from 16 laboratories in the multi-chemical
More informationsocial impairment. The following exclusion criteria applied: age under 18 years; weight under 45 kg or over 80 kg;
Postgrad Med J (1991) 67, 450-454 The Fellowship of Postgraduate Medicine, 1991 Low dose danazol in the treatment of the premenstrual syndrome Miriam Deeny, Robert Hawthorn and D. McKay Hart Division ofobstetrics
More informationHealth Products Regulatory Authority
1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25
More informationAUSTRALIAN PRODUCT INFORMATION PROPECIA (finasteride) Tablets QUALITATIVE AND QUANTITATIVE COMPOSITION
AUSTRALIAN PRODUCT INFORMATION PROPECIA (finasteride) Tablets NAME OF THE MEDICINE Finasteride QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet of PROPECIA contains 1 mg of finasteride.
More informationFINCAR Tablets (Finasteride)
Published on: 10 Jul 2014 FINCAR Tablets (Finasteride) Composition FINCAR Tablets Each film-coated tablet contains: Finasteride USP - 5 mg Dosage Form Tablet Pharmacology Pharmacodynamics Mechanism of
More informationDrug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More informationFinasteride for womens hair loss, mayo clinic
Finasteride for womens hair loss, mayo clinic The Borg System is 100 % Finasteride for womens hair loss, mayo clinic Jul 6, 2016. Many men taking finasteride experience a slowing of hair loss, and some
More informationFemale testosterone level chart
Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9
More informationPROPECIA Tablets Merck Sharp & Dhome
PROPECIA Tablets Merck Sharp & Dhome 1. NAME OF THE MEDICINAL PRODUCT PROPECIA 1 mg Film-Coated Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet of Propecia contains 1 mg of finasteride
More informationDUPROST Capsules (Dutasteride)
Published on: 10 Jul 2014 DUPROST Capsules (Dutasteride) Composition Each soft gelatin capsule contains: Dutasteride... 0.5 mg Dosage Form Capsule Pharmacology Pharmacodynamics Mechanism of Action Dutasteride
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More informationTestosterone Use and Effects
Parkland College Natural Sciences Poster Sessions Student Works 2013 Testosterone Use and Effects Brandon Mills Parkland College Recommended Citation Mills, Brandon, "Testosterone Use and Effects" (2013).
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationCLINICAL ASSESSMENT AND DIAGNOSIS
FERTILITY AND STERILITY VOL. 77, NO. 4, SUPPL 4, APRIL 2002 Copyright 2002 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. CLINICAL ASSESSMENT
More informationPHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor
PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme
More informationAssociate Professor Geoff Braatvedt
Associate Professor Geoff Braatvedt Endocrinologist Diabetologist and Physician Green Lane and Auckland City Hospitals Auckland 14:00-14:55 WS #145: Approach to Low Testosterone Values 15:05-16:00 WS #157:
More informationRelationship between Aerobic Training and Testosterone Levels in Male Athletes
Relationship between Aerobic Training and Testosterone Levels in Male Athletes Siu Yuen Ng Biology 493 13 th December, 2010 Abstract Salivary testosterone levels of 11 athletes and 15 non athletes were
More informationPROPECIA (finasteride) Tablets, 1 mg
9328505 PROPECIA (finasteride) Tablets, 1 mg DESCRIPTION PROPECIA * (finasteride), a synthetic 4-azasteroid compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that
More informationIcd 10 hormone replacement therapy male
Icd 10 hormone replacement therapy male 2018 ICD - 10 code for Hormone replacement therapy is Z79.890. Lookup the complete ICD 10 Code details for Z79.890. The ICD - 10 system requires that. TEENren who
More informationPROPECIA (Finasteride) Tablets, 1 mg
9328502 PROPECIA (Finasteride) Tablets, 1 mg DESCRIPTION PROPECIA * (finasteride), a synthetic 4-azasteroid compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that
More informationDonald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone
Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total
More informationAnavar For Sale Oxandrolone
Anavar For Sale Oxandrolone Anavar (oxandrolone C 19 H 30 O 3 ) is an anabolic steroid that provides outstanding results. The Anavar steroid is a synthesized version of testosterone that boosts lean muscle
More informationAndrogen Measurements
Chapter 5 / Androgen Measurements 63 Androgen Measurements Methods, Interpretation, and Limitations 5 Frank Z. Stanczyk SUMMARY Androgens are measured primarily in serum by direct and indirect (with one
More informationInsight into male menopause'
Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone
More informationSex Hormones and Metabolites
Accession # 00268796 Male Sample Report 123 A Street Sometown, CA 90266 Sex Hormones and Metabolites Ordering Physician: Precision Analytical DOB: 1967-08-09 Age: 50 Gender: Male Last Menstrual Period:
More informationClinical Significance of 5 -Reductase Activity
Clinical Significance of 5 -Reductase Activity By Jonathan Wright, MD and Barry Wheeler, ND 5 -Reductase (5AR) is the enzyme that catalyzes the conversion of (among others): Testosterone 5 -DHT Androstenedione
More informationNEW ZEALAND DATA SHEET. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 1 mg of finasteride.
1. PRODUCT NAME Profal, film coated tablets, 1 mg NEW ZEALAND DATA SHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 1 mg of finasteride. Excipient of known effect: Lactose
More informationNational Institute for Public Health and the Environment Annual CRL workshop 22 October Update on natural Hormone studies
2008 Annual CRL workshop 22 October 2008 Update on natural Hormone studies Natural hormone studies: update Possible approaches - C12/C13 ratio: can result in proof of abuse - Determination of intact esters
More informationIt is estimated that 24% to 90% of US men older than the age of
REPORTS Finasteride Versus Dutasteride: A Real-world Economic Evaluation Thomas C. Fenter, MD; M. Chris Runken, PharmD; Libby Black, PharmD; Michael Eaddy, PharmD, PhD It is estimated that 24% to 90% of
More informationTREATMENT OPTIONS FOR MALE HYPOGONADISM
TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,
More informationIntroduction to ICD-10-CM. Improving the Financial Health of the Practices we Serve.
Improving the Financial Health of the Practices we Serve. What is ICD-10???? ICD-10 replaces the ICD-9 code sets and includes updated NEW medical terminology and updated classification of diseases. The
More informationIOC Regulations on Female Hyperandrogenism
IOC Regulations on Female Hyperandrogenism The IOC Executive Board, in accordance with Rule 19.3.10 of the Olympic Charter, and pursuant to Rule 44 of the Olympic Charter, hereby issues the following regulations
More informationDisappearance of a virilizing adrenal tumor following therapy with cyproterone acetate
Endocrine-Related Cancer (2) 12 939 944 Disappearance of a virilizing adrenal tumor following therapy with cyproterone acetate A Lasco, E Morini, D Maglitto 1, A Campennì 2 and S Benvenga 3 Departments
More informationEFFECTS OF CLEAROGEN ACNE LOTION ON TESTOSTERONE METABOLISM IN RECONSTRUCTED HUMAN EPIDERMIS
IN VITRO BIOLOGICAL TESTING BIOalternatives The state-of-the-art laboratory Proposal n : AD070315C-2 Study n : AD070315A EFFECTS OF CLEAROGEN ACNE LOTION ON TESTOSTERONE METABOLISM IN RECONSTRUCTED HUMAN
More informationMALE HORMONE THERAPY OPTIONS
MALE HORMONE THERAPY OPTIONS The following tables have been compiled by Women s International Pharmacy staff pharmacists to represent some of the more frequently prescribed regimens for men. The Women
More informationPRODUCT INFORMATION PROVIRON
PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5
More informationMonitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc.
Mr Mark Newman Monitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc. 2 Avoiding Pitfalls in (B)HRT Monitoring and Picking the Right Lab Test Objectives: Outline how expected
More informationA Randomized, Parallel, Comparative Study of the Efficacy and Safety of Nafarelin Versus Danazol in the Treatment of Endometriosis in Taiwan
ORIGINAL ARTICLE A Randomized, Parallel, Comparative Study of the Efficacy and Safety of Nafarelin Versus Danazol in the Treatment of Endometriosis in Taiwan Ming-Huei Cheng 1,2, Bill Ken-Jen Yu 1 4, Sheng-Ping
More informationPRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)
PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone
More informationTreatment of endometriosis with danazol: report of a 6-year prospective study
FERTILITY AND STERILITY Copyright < 1985 The American Fertility Society Vol. 43 No.3 March 1985 Printed In U.S.A. Treatment of endometriosis with danazol: report of a 6-year prospective study Veasy C Buttram
More informationPRODUCT MONOGRAPH. pms-finasteride. Finasteride Tablets, House Standard Film-coated Tablets 1 mg. Type II 5 α-reductase Inhibitor
PRODUCT MONOGRAPH Pr pms-finasteride Finasteride Tablets, House Standard Film-coated Tablets 1 mg Type II 5 α-reductase Inhibitor PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Québec H4P
More informationAthletics Australia Transgender Policy
Athletics Australia Transgender Policy Policy Transgender Policy Eligibility of Athletes who have undergone sex reassignment to compete in women s competition. Related Policies Member Protection Policy,
More informationTESTOFEN. Anabolic & Androgenic Activity GENCOR PACIFIC, INC. Fenugreek Extract standardized for FENUSIDE TM. Copyright 2005 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920E. Orangethorpe Avenue, Suite B, Anaheim, CA. 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com manu@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationPROPECIA PRODUCT MONOGRAPH. Finasteride tablets, USP. Film-coated Tablets 1 mg. Type II 5α-reductase inhibitor. Date of Revision: October 1, 2018
PRODUCT MONOGRAPH PROPECIA Finasteride tablets, USP Film-coated Tablets 1 mg Type II 5α-reductase inhibitor Merck Canada Inc. 16750 route Transcanadienne Kirkland, QC H9H 4M7 Canada www.merck.ca Date of
More informationTherapeutic Guidelines - IADVL
AQ 0 0 0 0 0 IJDVL R0 Therapeutic Guidelines - IADVL Department of Dermatology, Venkat Charmalaya, Institute for Advanced Dermatology and Postgraduate Training, Bengaluru, Department of Dermatology, Mandya
More informationSUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE MEDICINAL PRODUCT Avodart 0.5 mg soft capsules. SUMMARY OF PRODUCT CHARACTERISTICS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. Excipient with known
More informationUpdate on the use of dutasteride in the management of benign prostatic hypertrophy
REVIEW Update on the use of dutasteride in the management of benign prostatic hypertrophy Joe Miller Thomas Tarter Division of Urology, Southern Illinois University School of Medicine, Springfield, IL,
More informationUse of Performance Enhancing Substances Good Chemistry Gone Bad. Evan M. Klass, M.D., F.A.C.P.
Use of Performance Enhancing Substances 2017 Good Chemistry Gone Bad Evan M. Klass, M.D., F.A.C.P. Doping the use of banned athletic performance-enhancing drugs by competitors Performance enhancing substances
More information